Organization: Northern Lipids Inc

DRDC licenses anti-anthrax technology to Aradigm

Defence R&D Canada (DRDC) has entered into an $2.9-million deal with Hayward CA-based Aradigm Corp to develop an aerosol delivery mechanism for liposomal-encapsulated ciproflaxicin for the treatment of respiratory infections caused by anthrax and other biological agents. The agreement will see DRDC fund Aradigm’s product and formulation development and initial pre-clinical studies, building on DRDC’s…